These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1829 related articles for article (PubMed ID: 17383080)

  • 21. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
    Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
    Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
    Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
    Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
    J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R; Kaasinen E; Rintala E; Group TF
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
    Sabichi AL; Lerner SP; Atkinson EN; Grossman HB; Caraway NP; Dinney CP; Penson DF; Matin S; Kamat A; Pisters LL; Lin DW; Katz RL; Brenner DE; Hemstreet GP; Wargo M; Bleyer A; Sanders WH; Clifford JL; Parnes HL; Lippman SM
    Clin Cancer Res; 2008 Jan; 14(1):224-9. PubMed ID: 18172274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
    Cho IC; Kim EK; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
    Karakiewicz PI; Benayoun S; Lewinshtein DJ; Chun FK; Shahrour K; Perrotte P
    Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 92.